Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 5/20 | 0.41 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.38 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.35 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.35 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.35 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.34 |
| ▸ | GAPDH | P04406 | 2/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21073914 | 1.00 | TYMP (0.41) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL29557743 | 1.00 | TYMP (0.41) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL23668111 | 1.00 | TYMP (0.41) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL18927161 | 0.98 | TYMP (0.41) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL17304195 | 0.98 | TYMP (0.41) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL18937384 | 0.98 | TYMP (0.41) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL21305113 | 0.98 | TYMP (0.41) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL21073979 | 0.98 | TYMP (0.41) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL24680543 | 0.98 | TYMP (0.41) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL20691430 | 0.98 | TYMP (0.41) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3868384-B1 | CYCLIC DINUCLEOTIDES AS STING (STIMULATOR OF INTERFERON GENES) AGONISTS | TAKEDA PHARMACEUTICALS CO (JP) | 2026-02-25 | — | — | EP | disclosed |
| US-20250205270-A1 | ANTIBODY-DRUG CONJUGATE PRECURSORS COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-06-26 | — | — | US | disclosed |
| US-12171777-B2 | Methods of making a cyclic dinucleotide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-12-24 | — | — | US | disclosed |
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-29 | — | — | US | disclosed |
| US-11666594-B2 | Antibody-drug conjugates comprising a cyclic dinucleotide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-06-06 | — | — | US | disclosed |
| US-20220211815-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | CHINOOK THERAPEUTICS, INC. | 2022-07-07 | — | — | US | disclosed |
| US-20210137962-A9 | CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-05-13 | — | — | US | disclosed |
| US-10980825-B2 | Cyclic dinucleotide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-20 | — | — | US | disclosed |
| US-20210106607-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-15 | — | — | US | disclosed |
| EP-3512861-B1 | CYCLIC DINUCLEOTIDES AS STING (STIMULATOR OF INTERFERON GENES) AGONISTS | TAKEDA PHARMACEUTICALS CO (JP) | 2021-02-17 | — | — | EP | disclosed |
| EP-2305805-A1 | DOUBLE-STRANDED POLYNUCLEOTIDE | Daiichi Sankyo Company, Limited (JP) | 2011-04-06 | — | — | EP | disclosed |
| US-7919473-B2 | IRNA agents targeting VEGF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-20060217330-A1 | Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering RNAs | BANK OF AMERICA, N.A. | 2006-09-28 | — | — | US | disclosed |
| US-20060094032-A1 | iRNA agents targeting VEGF | ALNYLAM PHARMACEUTICALS, INC. | 2006-05-04 | — | — | US | disclosed |
| US-20050059817-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | SIRNA THERAPEUTICS, INC. (US) | 2005-03-17 | — | — | US | disclosed |
| US-6686463-B2 | FEWER SYNTHETIC STEPS; INVOLVES FORMATION OF A 5',4'-BRIDGING SILYL PROTECTING GROUP TO FORM A FUSED SILOXANE ON THE FURAN RING | SIRNA THERAPEUTICS, INC. | 2004-02-03 | — | — | US | disclosed |
| EP-1313752-A2 | METHODS FOR SYNTHESIZING NUCLEOSIDES, NUCLEOSIDE DERIVATIVES AND NON-NUCLEOSIDE DERIVATIVES | RIBOZYME PHARMACEUTICALS, INC. (US) | 2003-05-28 | — | — | EP | disclosed |
| US-20020150936-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | RIBOZYME PHARMACEUTICALS, INC. | 2002-10-17 | — | — | US | disclosed |
| US-20020120129-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | RIBOZYME PHARMACEUTICALS, INC. | 2002-08-29 | — | — | US | disclosed |
| WO-2002018405-A2 | METHODS FOR SYNTHESIZING NUCLEOSIDES, NUCLEOSIDE DERIVATIVES AND NON-NUCLEOSIDE DERIVATIVES | RIBOZYME PHARMACEUTICALS, INCORPORATED (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | STING1, TLR9, CGAS | TYMP 408/4885PRMT6 1082/4885PRKAG1 291/4885 |
| US-12171777-B2 | Methods of making a cyclic dinucleotide | STING1, CGAS, MAVS | TYMP 289/4885PRMT6 1713/4885PRKAG1 60/4885 |
| US-20060094032-A1 | iRNA agents targeting VEGF | KDR, FLT4, SNRPE | TYMP 1464/4885PRMT6 1300/4885PRKAG1 926/4885 |
| US-20050059817-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | PNP, NSUN2, NT5C3B | TYMP 16/4885PRMT6 751/4885PRKAG1 2221/4885 |
| US-20210106607-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | STING1, TLR9, CGAS | TYMP 408/4885PRMT6 1082/4885PRKAG1 291/4885 |
| US-20210137962-A9 | CYCLIC DINUCLEOTIDE | STING1, CGAS, MAVS | TYMP 319/4885PRMT6 1417/4885PRKAG1 49/4885 |
| US-20020120129-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | PNP, NSUN2, NT5C3B | TYMP 17/4885PRMT6 627/4885PRKAG1 2199/4885 |
| US-10980825-B2 | Cyclic dinucleotide | STING1, CGAS, MAVS | TYMP 319/4885PRMT6 1417/4885PRKAG1 49/4885 |
| US-20250205270-A1 | ANTIBODY-DRUG CONJUGATE PRECURSORS COMPRISING A CYCLIC DINUCLEOTIDE | STING1, CGAS, TLR9 | TYMP 365/4885PRMT6 1404/4885PRKAG1 412/4885 |
| US-11666594-B2 | Antibody-drug conjugates comprising a cyclic dinucleotide | STING1, TLR9, CGAS | TYMP 408/4885PRMT6 1082/4885PRKAG1 291/4885 |
| US-20020150936-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | PNP, NSUN2, NT5C3B | TYMP 14/4885PRMT6 649/4885PRKAG1 2363/4885 |
| US-20220211815-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | STING1, IL15RA, IL15 | TYMP 664/4885PRMT6 3088/4885PRKAG1 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.